Page last updated: 2024-12-07

convicine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Convicine is a naturally occurring pyrimidine glycoside found in fava beans (Vicia faba). It is a potent inhibitor of the enzyme glucose-6-phosphate dehydrogenase (G6PD), which is responsible for the first step in the pentose phosphate pathway. This pathway is important for the production of NADPH, a reducing agent that protects cells from oxidative damage. Individuals with G6PD deficiency are unable to efficiently produce NADPH and are therefore susceptible to hemolytic anemia upon exposure to oxidative stressors, such as fava beans. Convicine is thought to be responsible for favism, a condition characterized by hemolytic anemia, jaundice, and other symptoms that can occur in individuals with G6PD deficiency who consume fava beans. Convicine has also been shown to exhibit antitumor activity in vitro. Its synthesis involves the condensation of cytosine and D-glucose. The study of convicine is important for understanding the pathogenesis of favism and for exploring its potential therapeutic applications.'

convicine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID88000
CHEBI ID3867
SCHEMBL ID4630048
MeSH IDM0050095

Synonyms (21)

Synonym
convicine
C08430
19286-37-4
6-amino-5-(b-d-glucopyranosyloxy)-2,4(1h,3h)-pyrimidinedione
AC1L3ETZ ,
6-amino-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1h-pyrimidine-2,4-dione
AC1Q6LTN ,
unii-6o6r2591x5
6o6r2591x5 ,
convicine [mi]
SCHEMBL4630048
CHEBI:3867
6-amino-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-1h-pyrimidine-2,4-dione
surecn4630048
6-amino-2-hydroxy-5-(beta-d-glucopyranosyloxy)-4-pyrimidinone
DTXSID60940958
4-amino-2,6-dihydroxypyrimidin-5-yl hexopyranoside
Q27106221
CS-0113903
HY-135738
6-amino-5-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)pyrimidine-2,4(1h,3h)-dione

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"This study in the rat established the effects that a broad-spectrum and poorly absorbed antibiotic, neomycin sulfate, had on the in vitro and in vivo hydrolysis of vicine and convicine by the intestinal microflora, and on vicine- and convicine-induced depletion of blood glutathione and the resulting toxicity."( Effect of neomycin on the hydrolysis and toxicity of vicine and convicine in rats.
Arbid, MS; Frohlich, AA; Madhyastha, MS; Marquardt, RR, 1993
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (31.82)18.7374
1990's6 (27.27)18.2507
2000's1 (4.55)29.6817
2010's6 (27.27)24.3611
2020's2 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.01 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index5.39 (4.65)
Search Engine Demand Index41.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]